Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KSP/QRH Dimer for Detection of Neoplasia in Barrett's Esophagus
NCT03852576Phase 1Terminated
- Sponsor
- University of Michigan
- Start
- May 2019
- Primary completion
- Nov 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of KSP-QRH-E3-IRDye800 in Barrett's esophagus, sponsored by University of Michigan. Primary endpoints: Binding of KSP/QRH dimer to EGFR and HER2, SFE ability to detect dimer by Signal-to-Noise Ratio (SNR) and 2 more. Started May 2019; status: terminated.
02
Drugs
KSP-QRH-E3-IRDye800
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT03852576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852576.